DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



MENOPUR® Versus FOLLISTIM®

Information source: Ferring Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility

Intervention: Menotropin (Drug); Progestrone vaginal insert (Drug); follitropin beta (Drug); Progesterone in oil (Drug); Ganirelix (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Ferring Pharmaceuticals

Official(s) and/or principal investigator(s):
Clinical Development Support, Study Director, Affiliation: Ferring Pharmaceuticals

Summary

To compare the efficacy and safety of highly purified menotropin (Menopur) with that of follitropin beta (FOLLISTIM) in patients who are undergoing gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles

Clinical Details

Official title: A Multi-Center, Randomized, Open-Label Evaluation of MENOPUR Versus FOLLISTIM in GnRH Antagonist Cycles

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of Participants With Ongoing Pregnancy at Week 8

Secondary outcome:

Number of Follicles Observed at Day 15

Number of Oocytes Retrieved at Day 18

Proportion of Oocytes Fertilized of the Total Number of Oocytes Retrieved

Number of Embryos Transferred at Three Stages of Development

Number of Embryos Frozen at Day 24

Participants With Cycle Cancellation Following One In Vitro Fertilization (IVF) Treatment Cycle

Participants With Biochemical Pregnancy at Day 38

Participants With Clinical Pregnancy at Week 7

Participants With Adverse Events (AEs), Including Ovarian Hyperstimulation Syndrome (OHSS)

Number of Live Births

Detailed description: This multicenter, randomized, open-label exploratory study will be performed in approximately 200 healthy females undergoing in vitro fertilization (IVF). Each study center will follow its study center standard practice for in vitro fertilization (IVF) within the study parameters as noted in this protocol. The study centers will use marketed products purchased from Schraft's Pharmacy for all phases of the study (down-regulation, stimulation, ovulation induction, and luteal support). Subjects will be randomly assigned prior to the start of stimulation to highly purified menotropin (Menopur®) or follitropin beta (Follistim Pen®) for stimulation and progesterone vaginal insert (Endometrin®) or progesterone in oil for luteal support. Subjects will return to the study center for regular scheduled clinic visits as required per in vitro fertilization (IVF) protocol at the site and at specified time periods during the cycle for estradiol (E2), progesterone (P4) and human chorionic gonadotropin (hCG) tests, and first serum pregnancy test. All subjects will be required to complete a final study visit at completion of luteal support or negative serum pregnancy test following embryo transfer.

Eligibility

Minimum age: 18 Years. Maximum age: 42 Years. Gender(s): Female.

Criteria:

Inclusion Criteria: 1. Pre-menopausal females between the ages of 18 and 42 years 2. Body mass index (BMI) of 18-34 3. Early follicular phase (day 2-4) Follicle stimulating hormone (FSH) <15 IU/L and Estradiol (E2) within normal limits 4. Documented history of infertility (e. g., unable to conceive for at least one year, or for 6 months for women >38 years of age, or bilateral tubal occlusion or absence, or male factor but excluding severe male factor requiring invasive or surgical sperm retrieval. Donor sperm may be used.) 5. Transvaginal ultrasound at screening consistent with findings adequate for assisted reproductive technology (ART) with respect to uterus and adnexa 6. Signed informed consent Exclusion Criteria: 1. Gestational or surrogate carrier, donor oocyte 2. Presence of any clinically relevant systemic disease (e. g., insulin-dependent diabetes mellitus, uterine cancer) 3. Surgical or medical condition which, in the judgment of the Investigator or Sponsor, may interfere with absorption, distribution, metabolism, or excretion of the drugs to be used 4. Previous In vitro fertilization (IVF) or Assisted reproductive technology (ART) failure due to a poor response to gonadotropins. Poor response is defined as development of 2 mature follicles or history of >2 previous failed in vitro fertilization (IVF) cycles. 5. History of recurrent pregnancy loss (>2). 6. Presence of abnormal uterine bleeding of undetermined origin 7. Current or recent substance abuse, including alcohol or smoking >10 cigarettes per day 8. Refusal or inability to comply with the requirements of the Protocol for any reason, including scheduled clinic visits and laboratory tests 9. Participation in any experimental drug study within 30 days prior to Screening 10. Severe male factor requiring invasive or surgical sperm retrieval (e. g., microsurgical epididymal sperm aspiration [MESA], testicular sperm extraction [TESE])

Locations and Contacts

Huntington Reproductive Center, Pasadena, California 91105, United States

San Diego Fertility Center, San Diego, California 92130, United States

Conceptions Reproductive Associates of Colorado, Littleton, Colorado 80129, United States

Women's Medical Research Group, LLC, Clearwater, Florida 33759, United States

The Advanced IVF Institute; Charles E. Miller, MD & Associates, Naperville, Illinois 60540, United States

A Woman's Center for Reproductive Medicine, Baton Rouge, Louisiana 70815, United States

Center for Assisted Reproduction, Bedford, Texas 76022, United States

Additional Information

Starting date: December 2008
Last updated: October 31, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017